Vitamin D trials found modest changes in bone turnover markers
Pooling trials showed small reductions in blood markers of bone turnover, although the featured trial found no statistically significant differences.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
Across the pooled trials, vitamin D was associated with small reductions in blood markers of bone turnover. The featured trial did not detect a statistically significant difference in either marker. These are laboratory outcomes: the abstract does not report whether fractures were reduced, so the marker changes cannot establish a fracture-prevention benefit.
This brief is based on the abstract alone. It does not describe participant characteristics or pooled follow-up durations, limiting assessment of who the pooled findings represent and over what period.
What researchers found
Plasma P1NP, a bone turnover marker
Average difference in within-trial change, vitamin D versus control. Pooled follow-up: Not reported in the abstract.
Individual and pooled results
In BEST-D, vitamin D levels rose, but P1NP and CTX did not differ significantly from placebo. Combining trials identified modest reductions in both bone turnover markers, producing a different statistical result from the individual trial.
What the markers mean
The study examined blood markers used to predict fracture risk. The authors called for further fracture-prevention trials in older people; changes in these markers alone do not demonstrate that supplements prevented fractures.
The original publication
Effects of vitamin D on biochemical markers of osteoporosis: a meta-analysis of randomised trials.
Alber CS, Halsey J, Emberson J et al.
Br J Nutr · 2026
- PubMed ID
- 42036999
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.